Loading
A phase 2 trial of ARX788 in HER2-positive breast cancer, run by Ambrx, Inc., active and no longer recruiting.
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) is a phase 2 interventional study registered as NCT04829604 by Ambrx, Inc., with 72 participants enrolled, started 2021-10-26 and due to reach its primary completion in 2026-12. Interventions recorded: ARX788.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ambrx, ARX788, Site-specific conjugation & linker chemistry, HER2-positive breast cancer.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/